Systemic Bio Wins the SLAS 2025 Innovation Award

Core Insights - Systemic Bio has won the SLAS 2025 Innovation Award for its technological advancements in laboratory science and automation [1][4] - The award recognizes the h-VIOS™ platform, which accelerates drug discovery using bioprinted human tissues, particularly in evaluating the safety of antibody-drug conjugates (ADCs) [2][4] - The technology allows for early identification of safety concerns that are typically only discovered during clinical trials, enhancing preclinical drug testing [2][3] Company Overview - Systemic Bio is a biotech company founded in 2022, focusing on drug discovery and development through bioprinted vascularized organ models [6] - The company operates under an ISO 7 clean room and a Quality Management System (QMS), capable of producing thousands of tissue models [3] - Systemic Bio collaborates with leading pharmaceutical companies to improve preclinical drug testing and reduce late-stage failures [3] Technology and Innovation - The h-VIOS™ platform is designed to create precise healthy and diseased tissues using biomaterials and human cells, enabling the study of drug effects at early stages of development [6] - The organ-on-chip systems can generate large datasets that leverage machine learning for human-relevant therapeutic insights [6] - The SLAS Innovation Award is presented annually to recognize forward-thinking technological advancements in laboratory science [4]